Hypertrophic cardiomyopathy surgery: Difference between revisions
Jump to navigation
Jump to search
Dima Nimri (talk | contribs) (/* Selection of Patients for Heart Transplantation (DO NOT EDIT) {{cite journal |author=Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW |title=2011 A...) |
Dima Nimri (talk | contribs) (/* Selection of Patients for Heart Transplantation (DO NOT EDIT) {{cite journal |author=Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW |title=2011 A...) |
||
| Line 20: | Line 20: | ||
|- | |- | ||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' Symptomatic children with HCM with restrictive physiology who are not responsive to or appropriate candidates for other therapeutic interventions should be considered for heart transplantation<ref name="pmid19782603">{{cite journal |author=Gajarski R, Naftel DC, Pahl E, ''et al.'' |title=Outcomes of pediatric patients with hypertrophic cardiomyopathy listed for transplant |journal=J. Heart Lung Transplant. |volume=28 |issue=12 |pages=1329–34 |year=2009 |month=December |pmid=19782603 |doi=10.1016/j.healun.2009.05.028 |url=}}</ref><ref name="pmid12015478">{{cite journal |author=Towbin JA |title=Cardiomyopathy and heart transplantation in children |journal=Curr. Opin. Cardiol. |volume=17 |issue=3 |pages=274–9 |year=2002 |month=May |pmid=12015478 |doi= |url=}}</ref>. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki> | | bgcolor="LightGreen"|<nowiki>"</nowiki>'''2.''' Symptomatic children with [[HCM]] with restrictive physiology who are not responsive to or appropriate candidates for other therapeutic interventions should be considered for heart transplantation<ref name="pmid19782603">{{cite journal |author=Gajarski R, Naftel DC, Pahl E, ''et al.'' |title=Outcomes of pediatric patients with hypertrophic cardiomyopathy listed for transplant |journal=J. Heart Lung Transplant. |volume=28 |issue=12 |pages=1329–34 |year=2009 |month=December |pmid=19782603 |doi=10.1016/j.healun.2009.05.028 |url=}}</ref><ref name="pmid12015478">{{cite journal |author=Towbin JA |title=Cardiomyopathy and heart transplantation in children |journal=Curr. Opin. Cardiol. |volume=17 |issue=3 |pages=274–9 |year=2002 |month=May |pmid=12015478 |doi= |url=}}</ref>. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki> | ||
|} | |} | ||
| Line 27: | Line 27: | ||
|colspan="1" style="text-align:center; background:LightCoral"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (Harm) | |colspan="1" style="text-align:center; background:LightCoral"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III]] (Harm) | ||
|- | |- | ||
|bgcolor="LightCoral"| <nowiki>"</nowiki>'''1.''' Heart transplantation should not be performed in mildly symptomatic patients of any age with HCM. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki> | |bgcolor="LightCoral"| <nowiki>"</nowiki>'''1.''' Heart transplantation should not be performed in mildly symptomatic patients of any age with [[HCM]]. ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])'' <nowiki>"</nowiki> | ||
|} | |} | ||
Revision as of 19:51, 28 October 2016
|
Hypertrophic Cardiomyopathy Microchapters |
|
Differentiating Hypertrophic Cardiomyopathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Hypertrophic cardiomyopathy surgery On the Web |
|
Directions to Hospitals Treating Hypertrophic cardiomyopathy |
|
Risk calculators and risk factors for Hypertrophic cardiomyopathy surgery |
Editors-In-Chief: C. Michael Gibson, M.S., M.D. [1], Cafer Zorkun, M.D. [2], Caitlin J. Harrigan [3], Martin S. Maron, M.D., and Barry J. Maron, M.D.
Cardiac Transplantation
Cardiac transplantation can be performed in patients with HOCM and has been associated with better post-operative survival than those patients transplanted for ischemic cardiomyopathy [1].
In cases that are refractory to all other forms of treatment, cardiac transplantation is an option.
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy (DO NOT EDIT)[2]
Selection of Patients for Heart Transplantation (DO NOT EDIT) [2]
| Class I |
| "1. Patients with advanced heart failure (end stage) and nonobstructive HCM not otherwise amenable to other treatment interventions, with EF less than or equal to 50% (or occasionally with preserved EF), should be considered for heart transplantation[3][4]. (Level of Evidence: B) " |
| "2. Symptomatic children with HCM with restrictive physiology who are not responsive to or appropriate candidates for other therapeutic interventions should be considered for heart transplantation[5][6]. (Level of Evidence: C) " |
| Class III (Harm) |
| "1. Heart transplantation should not be performed in mildly symptomatic patients of any age with HCM. (Level of Evidence: C) " |
References
- ↑ Martin S. Maron; Benjamin M. Kalsmith; James E. Udelson; Wenjun Li and David Denofrio.Survival Following Cardiac Transplantation in Patients with Hypertrophic Cardiomyopathy.doi: 10.1161/CIRCHEARTFAILURE.109.922872
- ↑ 2.0 2.1 Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW (2011). "2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons". Journal of the American College of Cardiology. 58 (25): e212–60. doi:10.1016/j.jacc.2011.06.011. PMID 22075469. Retrieved 2011-12-19. Unknown parameter
|month=ignored (help) - ↑ Harris KM, Spirito P, Maron MS; et al. (2006). "Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy". Circulation. 114 (3): 216–25. doi:10.1161/CIRCULATIONAHA.105.583500. PMID 16831987. Unknown parameter
|month=ignored (help) - ↑ Biagini E, Spirito P, Leone O; et al. (2008). "Heart transplantation in hypertrophic cardiomyopathy". Am. J. Cardiol. 101 (3): 387–92. doi:10.1016/j.amjcard.2007.09.085. PMID 18237606. Unknown parameter
|month=ignored (help) - ↑ Gajarski R, Naftel DC, Pahl E; et al. (2009). "Outcomes of pediatric patients with hypertrophic cardiomyopathy listed for transplant". J. Heart Lung Transplant. 28 (12): 1329–34. doi:10.1016/j.healun.2009.05.028. PMID 19782603. Unknown parameter
|month=ignored (help) - ↑ Towbin JA (2002). "Cardiomyopathy and heart transplantation in children". Curr. Opin. Cardiol. 17 (3): 274–9. PMID 12015478. Unknown parameter
|month=ignored (help)